Acute paronychia caused by lapatinib therapy

Rigopoulos, Dimitrios; Gregoriou, Stamatis; Belyayeva, Y.; Larios, George; Gkouvi, Aikaterini; Katsambas, Andreas

doi:10.1111/j.1365-2230.2008.02928.x

Cited by 11 publications

(4 citation statements)

References 6 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We believe the lack of lapatinib studies that fit our criteria is also due to underreporting and that the drug does cause nail toxicities, as nail disorders, including paronychia, have been reported as a side effect of lapatinib in few studies. 14,51,52 In addition, the low incidence of high-grade nail toxicity can be attributed to the fact that version 3.0 of the CTCAE included grade 3 nail changes (interfering with daily life), whereas version 2.0 only included ratings up to grade 2. It is possible that the reported severity of nail changes is underestimated in many of the studies as a result of the lack of a more specific rating.…”

Section: Discussionmentioning

confidence: 99%

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Garden

Lacouture

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Garden

Lacouture

2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…[ 4 48 49 50 51 ] Mechanisms include an increase in the retinoic acid concentrations and inhibition of EGFR. [ 2 52 ] Pemphigus [ Figure 7 ], psoriasis [ Figure 8 ] and reactive arthritis may also present with CP, although presentation as AP is more common. [ 2 8 , 9 ]…”

Section: Hronic P Aronychiamentioning

confidence: 99%

Acute and chronic paronychia revisited: A narrative review

Relhan¹,

Bansal²

2022

J Cutan Aesthet Surg

View full text Add to dashboard Cite

Paronychia refers to the inflammation of the tissue which immediately surrounds the nail and it can be acute (<6 weeks duration) or chronic (>6 weeks duration). Disruption of the protective barrier between the nail plate and the adjacent nail fold preceded by infectious or noninfectious etiologies results in the development of paronychia. A combination of general protective measures, and medical and/or surgical interventions are required for management. This review explores the pathogenesis, clinical features, differential diagnosis, medical, and surgical management of paronychia. For the purpose of this review, we searched the PubMed, Cochrane, and Scopus databases using the following keywords, titles, and medical subject headings (MeSH): acute paronychia, chronic paronychia, and paronychial surgeries. Relevant review articles, original articles, and case reports/series published till February 2020 were included in this study.

show abstract

“…EGFRIs are generally well tolerated and do not have any of the severe systemic side effects seen with ‘traditional’ cytotoxic agents. However, these agents have been associated with major cutaneous side effects [4,5]. Papulopustular eruption is the most common skin toxicity and occurs at a rate of 45–100% of treated patients, depending on the agent.…”

Section: Introductionmentioning

confidence: 99%

Pimecrolimus Cream 1% for the Treatment of Papulopustular Eruption Related to Epidermal Growth Factor Receptor Inhibitors: A Case Series and a Literature Review of Therapeutic Approaches

et al. 2010

Self Cite

View full text Add to dashboard Cite

Background: Cutaneous side effects of epidermal growth factor receptor inhibitors (EGFRIs) are very frequent and well known. The aim of our study was to investigate the efficacy and safety of pimecrolimus 1% cream in the treatment of papulopustular eruption caused by EGFRIs and to review the relevant literature on therapeutic approaches. Methods: Twenty cancer patients being treated with EGFRIs were included in the study. Nine of the patients showed grade 1 and 11 showed grade 2 papulopustular eruption. All patients were treated with pimecrolimus 1% cream, which was applied twice daily. Patients with grade 2 eruption also received systemic minocycline 100 mg/day. Results: All patients with grade 1 eruption responded to treatment, with 4/9 experiencing complete resolution of the lesions 2 weeks after the initiation of treatment. Five out of 11 patients with grade 2 eruption had more than 50% improvement in erythema and pustules, and 1 had complete resolution of the skin lesions. Two patients did not respond to treatment but were significantly improved after substitution of pimecrolimus 1% cream with metronidazole 1% cream. No side effects were recorded. Conclusions: Our case series shows that pimecrolimus cream may be an effective and safe approach in the management of papulopustular eruption related to EGFRIs.

show abstract

Acute paronychia caused by lapatinib therapy

Cited by 11 publications

References 6 publications

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis

Acute and chronic paronychia revisited: A narrative review

Pimecrolimus Cream 1% for the Treatment of Papulopustular Eruption Related to Epidermal Growth Factor Receptor Inhibitors: A Case Series and a Literature Review of Therapeutic Approaches

Contact Info

Product

Resources

About